UPC
Universe Pharmaceuticals Inc. (UPC) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Net debt to EBITDA of 13.8x and negative interest coverage leave UPC far more exposed to refinancing and covenant pressure than peers with lower leverage and positive coverage.
A 428-day cash conversion cycle, driven by 421 days of receivables, ties up working capital and leaves UPC less resilient than peers with faster cash realization.
Negative interest coverage indicates operating earnings are not currently supporting financing costs, increasing sensitivity to rate or margin pressure versus better-covered peer models.
Current and quick ratios above 3.7 provide liquidity, but they do not offset the much weaker earnings-based debt service profile relative to peers with stronger cash generation.
Opportunities
High current and quick ratios suggest UPC has near-term liquidity flexibility, which can support operations better than peers facing tighter short-term funding conditions.
If receivables collection normalizes from the current 421-day level, working-capital release could improve cash generation more sharply than in peers with already efficient cycles.
The low debt-to-equity ratio of 0.17x leaves balance-sheet capacity that could be more usable than peers if operating performance stabilizes and coverage improves.
Because leverage is concentrated in EBITDA terms rather than equity terms, any margin recovery could translate into faster relative improvement than for more structurally indebted peers.
Overall Score
UPC’s strong liquidity and balance-sheet capacity are outweighed by very weak earnings-based leverage and working-capital efficiency versus peers, leaving positioning fragile despite some recovery optionality.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Universe Pharmaceuticals Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
